Impact of filgotinib on pain control in the phase 3 FINCH studies
An erratum to this article was published (RMD Open, 4 Apr 2024 ↗)
Authors' conclusion
In all RA populations studied, pain improvements occurred from week 2 and were sustained over time. In FINCH 1, filgotinib 100 mg provided similar pain amelioration to adalimumab, whereas filgotinib 200 mg resulted in greater pain improvement and higher proportion of patients with residual pain ≤10 or ≤20 mm and meeting DAS28-CRP remission criteria.
Study context
- Population
- Patients with rheumatoid arthritis (RA) in the FINCH 1–3 studies
- Comparison
- Filgotinib 200 mg or 100 mg vs adalimumab vs placebo, each plus MTX
Primary result
As reported in the abstract
VAS pain ≤20 mm plus DAS28-CRP remission (FINCH 1) · week 24
Further findings
VAS pain ≤10 mm plus DAS28-CRP remission (FINCH 1) · week 24
Visual analogue scale (VAS) pain ≤10 mm plus DAS28-CRP remission (FINCH 1) · week 24
- Similar pattern for Clinical Disease Activity Index (CDAI) remission
- Time with VAS pain ≤10 or ≤20 mm longest with filgotinib 200 mg; comparable between adalimumab and filgotinib 100 mg
- Similar findings for filgotinib in FINCH 2 and 3
Original publication
Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD Open. Published 12 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →